MCL Literature Feed

A novel gene-editing method creates safer allogeneic CAR-T cells, potentially offering a more accessible 'off-the-shelf' cellular therapy option for MCL patients.

This review summarizes the rapid clinical integration of T-cell engaging therapies (CAR-T, bispecifics) for B-NHL, including MCL, and outlines future strategies like earlier use and novel constructs.

Pretargeted anti-CD20 radioimmunotherapy safely intensifies BEAM conditioning before autologous transplant in high-risk B-cell lymphomas, including MCL, offering a feasible new consolidation strategy.

This review summarizes the evolution of BTK inhibitors, from covalent to reversible agents, to overcome resistance and toxicity, highlighting their central role in current and future MCL therapies.

This case report identifies chronic enteroviral meningoencephalitis as a severe neurotoxicity of rituximab maintenance in MCL, demonstrating successful resolution with intravenous immunoglobulins (IVIg) and fluoxetine.

This review summarizes preclinical nanocarrier strategies designed to improve ibrutinib's bioavailability and targeted delivery, potentially enhancing efficacy and reducing off-target toxicity for MCL patients in the future.

This case report identifies mantle cell lymphoma as a rare cause of secondary thrombotic microangiopathy, diagnosed via kidney biopsy and resolved with chemotherapy, expanding the differential for this complication.

An albumin nanocomplex of the BCL-2/xL inhibitor APG-1252 reduces thrombocytopenia and enhances anti-MCL efficacy in mouse models, offering a potential strategy to improve the therapeutic window.

Long-term follow-up (37.2 months) in Japanese relapsed/refractory MCL patients shows the ibrutinib-venetoclax combination yields durable complete responses (83% CR), high MRD negativity, and a manageable safety profile.

This study evaluates the novel, chemotherapy-free combination of PI3Ki copanlisib and BCL2i venetoclax as a new targeted therapy for patients with relapsed/refractory mantle cell lymphoma.

This large real-world study confirms brexucabtagene autoleucel's high efficacy (91% ORR, 63% 1-yr PFS) in R/R MCL, supporting its standard-of-care role and suggesting earlier use improves outcomes.

This review provides a framework for selecting frontline therapies for older MCL patients, weighing less-intensive chemoimmunotherapy against novel agents like BTK inhibitors based on patient-specific factors.

This preclinical study engineers novel nanocarriers for cytarabine, aiming to improve drug delivery and anti-lymphoma efficacy, which could enhance existing high-dose MCL chemotherapy regimens.

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

In a US community setting, real-world data shows MCL patients on zanubrutinib had significantly longer treatment duration and adherence compared to acalabrutinib and ibrutinib, suggesting better persistence.

Acalabrutinib plus rituximab successfully resolved paraneoplastic glomerulonephritis in an MCL patient, offering a new treatment approach for this rare renal complication.

All BTK inhibitors impair platelet aggregation in MCL as a class effect, regardless of BTK specificity or dose, providing a clear mechanism for the bleeding risk seen with these agents.

Ibrutinib can cause rare but severe hepatic subcapsular hematomas in relapsed MCL; ultrasound is a key tool for early diagnosis and monitoring of this bleeding complication.

This case report highlights the risk of life-threatening invasive aspergillosis in an elderly MCL patient with chronic neutropenia, underscoring the need for high clinical suspicion for fungal infections.

This case series reports fatal Hepatitis B reactivation with ibrutinib and breakthrough reactivation on zanubrutinib despite prophylaxis, highlighting the need for vigilant HBV monitoring with all BTKis.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.

In untreated mantle cell lymphoma, adding acalabrutinib to bendamustine-rituximab significantly improves progression-free survival with manageable toxicity, offering a potentially safer chemoimmunotherapy combination than ibrutinib-based regimens.

This review outlines key clinical strategies for patient selection, toxicity management, and overcoming resistance to maximize the efficacy and safety of CAR-T therapy in relapsed/refractory MCL.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

This case report describes a rare, rapid progression from acute myopericarditis to pericardial calcification after initial CHOP chemotherapy, highlighting a severe, early-onset cardiotoxicity risk with this regimen.